Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Cash & Equivalents for 6 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 99.41% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Dec 2025, down 99.41% year-over-year, with the annual reading at $100000.0 for FY2025, 99.41% down from the prior year.
  • Cash & Equivalents hit $100000.0 in Q4 2025 for Rapid Micro Biosystems, roughly flat from $100000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $219.6 million in Q3 2021 to a low of $100000.0 in Q1 2023.
  • Historically, Cash & Equivalents has averaged $30.5 million across 5 years, with a median of $16.9 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: crashed 99.91% in 2022 and later skyrocketed 18806.0% in 2025.
  • Year by year, Cash & Equivalents stood at $300000.0 in 2021, then skyrocketed by 8921.33% to $27.1 million in 2022, then decreased by 10.27% to $24.3 million in 2023, then crashed by 30.36% to $16.9 million in 2024, then plummeted by 99.41% to $100000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for RPID at $100000.0 in Q4 2025, $100000.0 in Q3 2025, and $200000.0 in Q2 2025.